.Nature Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of patients along with HER2+ innovative bosom cancer as well as active or steady mind metastases showed steady intracranial activity as well as systemic efficacy of T-DXd.